The Institute of Hypoxia Medicine, Capital Medical University, is the first specialized research institutions in this field in China. The major aims of the Institute are to understand the role of hypoxia-mediated impairment in the pathogenesis of the diseases and to improve people's quality of life and the operational capability in the special environmental condition. The Institute of Hypoxia Medicine was established in2004. Since then, great progress has been made overpass 10 years. The Institute was renamed as "Beijing Key Laboratory of Hypoxia Conditioning Translational Medicine”by the Beijing Municipal Science and Technology Commission in June 2014. The Institute of Hypoxia Medicine is dedicated to build up a first-class laboratory in China as the goal, and toprovide clinical services as the purpose with discipline advantage.In addition, the Institute will organize the fundamental, forward-looking, strategic science and technology innovational activities closely related to clinical application. Through the integration of basic and clinical advantages of resources, we will build excellent research team and advanced open platform. The main research topics include: (1) to study the mechanisms of ischemic preconditioning; (2) to study the synergetic neuroprotection of ischemic preconditioning in combination ofother treatments; (3) to establish the technical specifications of ischemic preconditioning in the treatment of cardiovascular disease, cerebrovascular disease, and peripheral vascular disease, and (4) to develop and improve ischemic preconditioning transformed products.Based on our own characteristics and advantages, strengthening open cooperation and resource sharing of laboratory Our laboratory has establishedstrategic cooperative relationshipwith the University of North Texas Health Science Center, and Wayne University in the United States, and a number of researchers have been trained as a visiting scholar in these Universities.